Does the media refer more to CGEN or CADL?

In the previous week, Candel Therapeutics had 8 more articles in the media than Compugen. MarketBeat recorded 9 mentions for Candel Therapeutics and 1 mentions for Compugen. Compugen's average media sentiment score of 0.75 beat Candel Therapeutics' score of -0.07 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, CGEN or CYRX?

CryoPort has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compugen $72.76M 2.96 $35.34M $0.37 6.16 CryoPort $182.94M 4.27 $78.30M $1.35 11.47

Does the media prefer CGEN or CYRX?

In the previous week, Compugen and Compugen both had 1 articles in the media. Compugen's average media sentiment score of 0.75 beat CryoPort's score of 0.00 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, OCS or CGEN?

Compugen has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 564.61 -$119.44M -$2.13 N/A Compugen $72.76M 2.96 $35.34M $0.37 6.16

Is OCS or CGEN more profitable?

Compugen has a net margin of 47.97% compared to Oculis' net margin of -8,460.67%. Compugen's return on equity of 47.72% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Compugen 47.97% 47.72% 27.51%

Does the media prefer OCS or CGEN?

In the previous week, Oculis had 3 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Oculis and 1 mentions for Compugen. Oculis' average media sentiment score of 1.24 beat Compugen's score of 0.75 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, CGEN or IVA?

Compugen has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compugen $72.76M 2.96 $35.34M $0.37 6.16 Inventiva $5.07M 160.19 -$400.67M N/A N/A

Does the media refer more to CGEN or IVA?

In the previous week, Inventiva had 2 more articles in the media than Compugen. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Compugen. Compugen's average media sentiment score of 0.75 beat Inventiva's score of 0.23 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Compugen (CGEN) Competitors

$2.28 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.28 0.00 (-0.18%)

As of 07/2/2026 07:55 PM Eastern

Compare

CGEN vs. ESPR, CADL, CYRX, OCS, and IVA

Should you buy Compugen stock or one of its competitors? MarketBeat compares Compugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compugen include Esperion Therapeutics (ESPR), Candel Therapeutics (CADL), CryoPort (CYRX), Oculis (OCS), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.

How does Compugen compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Compugen had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 1 mentions for Compugen and 0 mentions for Esperion Therapeutics. Compugen's average media sentiment score of 0.75 beat Esperion Therapeutics' score of 0.00 indicating that Compugen is being referred to more favorably in the news media.

Company	Overall Sentiment
Esperion Therapeutics	Neutral
Compugen	Positive

Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Compugen has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market.

Compugen has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16

Esperion Therapeutics presently has a consensus target price of $5.54, suggesting a potential upside of 75.32%. Compugen has a consensus target price of $5.00, suggesting a potential upside of 119.30%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Compugen has a net margin of 47.97% compared to Esperion Therapeutics' net margin of 0.12%. Compugen's return on equity of 47.72% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Compugen	47.97%	47.72%	27.51%

Summary

Compugen beats Esperion Therapeutics on 15 of the 17 factors compared between the two stocks.

How does Compugen compare to Candel Therapeutics?

Compugen (NASDAQ:CGEN) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Compugen has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Compugen has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, meaning that its stock price is 152% less volatile than the broader market.

Compugen has a net margin of 47.97% compared to Candel Therapeutics' net margin of 0.00%. Compugen's return on equity of 47.72% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Candel Therapeutics	N/A	-60.42%	-41.33%

In the previous week, Candel Therapeutics had 8 more articles in the media than Compugen. MarketBeat recorded 9 mentions for Candel Therapeutics and 1 mentions for Compugen. Compugen's average media sentiment score of 0.75 beat Candel Therapeutics' score of -0.07 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

12.2% of Compugen shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Compugen currently has a consensus target price of $5.00, suggesting a potential upside of 119.30%. Candel Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 83.11%. Given Compugen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Compugen is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Compugen beats Candel Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Compugen compare to CryoPort?

Compugen (NASDAQ:CGEN) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Compugen has a net margin of 47.97% compared to CryoPort's net margin of 41.57%. Compugen's return on equity of 47.72% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
CryoPort	41.57%	-7.92%	-4.79%

Compugen currently has a consensus price target of $5.00, suggesting a potential upside of 119.30%. CryoPort has a consensus price target of $15.11, suggesting a potential downside of 2.45%. Given Compugen's higher possible upside, analysts plainly believe Compugen is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Compugen has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

In the previous week, Compugen and Compugen both had 1 articles in the media. Compugen's average media sentiment score of 0.75 beat CryoPort's score of 0.00 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.2% of Compugen shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 10.0% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CryoPort has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16
CryoPort	$182.94M	4.27	$78.30M	$1.35	11.47

Summary

CryoPort beats Compugen on 8 of the 15 factors compared between the two stocks.

How does Compugen compare to Oculis?

Oculis (NASDAQ:OCS) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Oculis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Compugen has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market.

Compugen has a net margin of 47.97% compared to Oculis' net margin of -8,460.67%. Compugen's return on equity of 47.72% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Compugen	47.97%	47.72%	27.51%

22.3% of Oculis shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Oculis had 3 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Oculis and 1 mentions for Compugen. Oculis' average media sentiment score of 1.24 beat Compugen's score of 0.75 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16

Oculis presently has a consensus target price of $38.33, indicating a potential upside of 171.48%. Compugen has a consensus target price of $5.00, indicating a potential upside of 119.30%. Given Oculis' higher possible upside, equities analysts plainly believe Oculis is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Compugen beats Oculis on 10 of the 16 factors compared between the two stocks.

How does Compugen compare to Inventiva?

Compugen (NASDAQ:CGEN) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Compugen has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Compugen has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16
Inventiva	$5.07M	160.19	-$400.67M	N/A	N/A

12.2% of Compugen shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Compugen has a net margin of 47.97% compared to Inventiva's net margin of 0.00%. Compugen's return on equity of 47.72% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Inventiva	N/A	N/A	N/A

Compugen currently has a consensus target price of $5.00, indicating a potential upside of 119.30%. Inventiva has a consensus target price of $16.56, indicating a potential upside of 323.42%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

In the previous week, Inventiva had 2 more articles in the media than Compugen. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Compugen. Compugen's average media sentiment score of 0.75 beat Inventiva's score of 0.23 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inventiva beats Compugen on 8 of the 15 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEN vs. The Competition

Export

Metric	Compugen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$215.58M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	6.16	21.61	28.02	24.70
Price / Sales	2.96	340.19	540.37	99.49
Price / Cash	6.10	147.12	49.26	57.09
Price / Book	2.09	8.66	10.96	6.46
Net Income	$35.34M	$23.81M	$3.57B	$337.01M
7 Day Performance	8.83%	3.39%	2.12%	1.69%
1 Month Performance	8.57%	10.81%	5.25%	3.81%
1 Year Performance	28.09%	62.61%	33.29%	23.90%

Compugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEN Compugen	3.7975 of 5 stars	$2.28 flat	$5.00 +119.3%	+28.1%	$215.58M	$72.76M	6.16	70	Gap Down
ESPR Esperion Therapeutics	2.1397 of 5 stars	$3.16 +0.2%	$5.54 +75.6%	+169.9%	$813.01M	$403.14M	N/A	200
CADL Candel Therapeutics	2.6436 of 5 stars	$11.01 +6.2%	$18.00 +63.6%	+92.7%	$801.94M	N/A	N/A	60	News Coverage Insider Trade
CYRX CryoPort	2.9392 of 5 stars	$15.65 -3.9%	$15.11 -3.4%	+102.7%	$788.76M	$176.18M	11.59	1,186	Positive News
OCS Oculis	3.5502 of 5 stars	$13.37 +2.1%	$38.33 +186.7%	-25.5%	$774.32M	$1.45M	N/A	2	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compugen (CGEN) Competitors

CGEN vs. ESPR, CADL, CYRX, OCS, and IVA

How does Compugen compare to Esperion Therapeutics?

Summary

How does Compugen compare to Candel Therapeutics?

Summary

How does Compugen compare to CryoPort?

Summary

How does Compugen compare to Oculis?

Summary

How does Compugen compare to Inventiva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compugen (CGEN) Competitors

CGEN vs. ESPR, CADL, CYRX, OCS, and IVA

How does Compugen compare to Esperion Therapeutics?

Do insiders & institutionals hold more shares of ESPR or CGEN?

Does the media prefer ESPR or CGEN?

Which has more volatility & risk, ESPR or CGEN?

Which has stronger valuation & earnings, ESPR or CGEN?

Do analysts rate ESPR or CGEN?

Is ESPR or CGEN more profitable?

Summary

How does Compugen compare to Candel Therapeutics?

Which has preferable earnings and valuation, CGEN or CADL?

Which has more volatility and risk, CGEN or CADL?

Is CGEN or CADL more profitable?

Does the media refer more to CGEN or CADL?

Do insiders and institutionals have more ownership in CGEN or CADL?

Do analysts rate CGEN or CADL?

Summary

How does Compugen compare to CryoPort?

Is CGEN or CYRX more profitable?

Do analysts prefer CGEN or CYRX?

Which has more risk and volatility, CGEN or CYRX?

Does the media prefer CGEN or CYRX?

Do insiders & institutionals have more ownership in CGEN or CYRX?

Which has better valuation & earnings, CGEN or CYRX?

Summary

How does Compugen compare to Oculis?

Which has more risk & volatility, OCS or CGEN?

Is OCS or CGEN more profitable?

Do insiders and institutionals believe in OCS or CGEN?

Does the media prefer OCS or CGEN?

Which has preferable valuation & earnings, OCS or CGEN?

Do analysts prefer OCS or CGEN?

Summary

How does Compugen compare to Inventiva?

Which has more volatility & risk, CGEN or IVA?

Which has higher earnings and valuation, CGEN or IVA?

Do institutionals and insiders believe in CGEN or IVA?

Is CGEN or IVA more profitable?

Do analysts recommend CGEN or IVA?

Does the media refer more to CGEN or IVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools